The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-Met-urokinase plasminogen activator-plasmin proteolytic network

Cancer Research

Volumn 60, Issue 2, 2000, Pages 342-349

  Webb, Craig P ^a,e   Hose, Curtis D ^b   Koochekpour, Shahriar ^a   Jeffers, Michael ^c   Oskarsson, Marianne ^a   Sausville, Edward ^d   Monks, Anne ^b   Vande Woude, George F ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c CURAGEN CORPORATION   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELDANAMYCIN; PLASMIN; PLASMINOGEN ACTIVATOR; SCATTER FACTOR; UROKINASE;

ANTIMICROBIAL ACTIVITY; ARTICLE; CANCER INVASION; CELL MOTILITY; CELL PROLIFERATION; DOWN REGULATION; HUMAN; HUMAN CELL; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; BENZOQUINONES; CELL DIVISION; CELL LINE; CELL LINE, TRANSFORMED; HEPATOCYTE GROWTH FACTOR; HUMANS; LACTAMS, MACROCYCLIC; MICE; PLASMIN; PROTO-ONCOGENE PROTEINS C-MET; QUINONES; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0034650543     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Park, M., Dean, M., Cooper, C. S., Schmidt, M., O'Brien, S. J., Blair, D. G., and Vande Woude, G. F. Mechanism of met oncogene activation. Cell, 45: 895-904, 1986.
2. Bottaro, D. P., Rubin, J. S., Faletto, D. L., Chan, A. M., Kmiecik, T. E., Vande Woude, G. F., and Aaronson, S. A. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (Washington DC), 251: 802-804, 1991.
3. Gherardi, E., Sharpe, M., Lane, K., Sirulnik, A., and Stoker, M. Hepatocyte growth factor/scatter factor (HGF/SF), the c-met receptor and the behaviour of epithelial cells. Symp. Soc. Exp. Biol., 47: 163-181, 1993.
4. Vande Woude, G. F., Jeffers, M., Cortner, J., Alvord, G., Tsarfaty, I., and Resau, J. Met-HGF/SF. Tumorigenesis, Invasion, and Metastasis. In: G. R. Bock, and J. A. Goode (eds.), CIBA Foundation Symposium: Plasminogen-Related Growth Factors, Vol. 212, pp. 119-132. West Sussex: John Wiley & Sons Ltd., 1997.
5. Rubin, J. S., Bottaro, D. P., and Aaronson, S. A. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim. Biophys. Acta, 1155: 357-371, 1993.
6. Jeffers, M., Rong, S., and Vande Woude, G. F. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J. Mol. Med., 74: 505-513, 1996.
7. Jeffers, M., Rong, S., and Vande Woude, G. F. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-Met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol. Cell. Biol., 16: 1115-1125, 1996.
8. Rong, S., Bodescot, M., Blair, D., Dunn, J., Nakamura, T., Mizuno, K., Park, M., Chan, A., Aaronson, S., and Vande Woude, G. F. Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor. Mol. Cell. Biol., 12: 5152-5158, 1992.
9. Rong, S., Segal, S., Anver, M., Resau, J. H., and Vande Woude, G. F. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl. Acad. Sci. USA, 91: 4731-4735, 1994.
10. Jeffers, M., Rong, S., Oskarsson, M., Anver, M., and Vande Woude, G. F. Autocrine hepatocyte growth factor/scatter factor-Met signaling induces transformation and the invasive/metastatic phenotype in C127 cells. Oncogene, 13: 853-861, 1996.
11. Schmidt, L., Duh, F-M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allilmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J. M., Walter, M. M., Tsui, L-C., Geil, L., Orcutt, M. L., Stackhouse, T., Lipan, J., Slife, L., Brauch, H., Decker, J., Niehans, G., Hughson, M. D., Moch, H., Storkel, S., Lerman, M. I., Linehan, W. M., and Zbar, B. Germ-line and somatic mutations in the tyrosine kinase domain of the Met proto-oncogene in papillary renal carcinomas. Nat. Genet., 16: 68-73, 1997.
12. Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C. P., Weirich, G., Kishida, T., Zbar, B., and Vande Woude, G. F. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. USA, 94: 11445-11450, 1997.
13. Jeffers, M., Fiscella, M., Webb, C. P., Anver, M., Koochekpour, S., and Vande Woude, G. F. The mutationally activated Met receptor mediates motility and metastasis. Proc. Natl. Acad. Sci. USA, 95: 14417-14422, 1998.
14. Johnsen, M., Lund, L. R., Romer, J., Almholt, K., and Dano, K. Cancer invasion and tissue remodeling; common themes in proteolytic matrix degradation. Curr. Opin. Cell Biol., 10: 667-671, 1998.
15. Pepper, M. S., Matsumoto, K., Nakamura, T. Orci, L., and Montesano, R. Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J. Biol. Chem., 267: 20493-20496, 1992.
16. Ried, S., Jager, C., Jeffers, M., Vande Woude, G. F., Graeff, H., Schmitt, M., and Lengyel, E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J. Biol. Chem., 274: 16377-16386, 1999.
17. Blasi, F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays, 15: 105-111, 1993.
18. Ellis, V., Pyke, C., Eriksen, J., Solberg, H., and Dano, K. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann. N. Y. Acad, Sci., 667: 13-31, 1992.
19. Kugler, A. Matrix metalloproteinases and their inhibitors. Anticancer Res., 19: 1589-1592, 1999.
20. Reuning, U., Magdolen, V., Wilhelm, O., Fischer, K., Lutz, V., Graeff, H., and Schmitt, M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis. Int. J. Oncol., 13: 893-906, 1998.
21. Webb, C. P., Lane, K., Dawson, A. P., Vande Woude, G. F., and Warn, R. M. C-Met signaling in an HGF/SF-insensitive variant MDCK cell line with constitutive motile/ invasive behaviour. J. Cell Sci., 109: 2371-2381, 1996.
22. Park, M., Dean, M., Kaul, K., Braun, M. J., Gonda, M. A., and Vande Woude, G. F. Sequence of met proto-oncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl. Acad. Sci. USA, 84: 6379-6383, 1987.
23. Rong, S., Oskarsson, M., Faletto, D., Tsarfaty, I., Resau, J. H., Nakamura, T., Rosen, E., Hopkins, R. F., and Vande Woude, G. F. Tumorigenesis induced by co-expression of human hepatocyte growth factor and the human met proto-oncogene leads to high levels of expression of the ligand and receptor. Cell Growth Differ., 4: 563-569, 1993.
24. Towle, M. J., Lee, A., Maduakor, E. C., Schwartz, C. E., Bridges, A. J., and Littlefield, B. A. Inhibition of urokinase by 4-substituted benzo[b] thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res., 53: 2553-2559, 1993.
25. Monks, A., Scudiero, D., Skehan, P., Shoemaker, R., Paull, K., Vistica, D., Hose, C., Langley, J., Cronise, P., Vaigro-Wolff, A., Gray-Goodrich, M., Campbell, H., Mayo, J., and Boyd, M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst., 83: 757-766, 1991.
26. Stoker, M., Gherardi, E., Perryman, M., and Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature (Lond.), 327: 239-242, 1987.
27. Koochekpour, S., Jeffers, M., Rulong, S., Klineberg, E., Taylor, G., Hudson, E. A., Resau, J. H., and Vande Woude, G. F. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res., 57: 5391-5398, 1997.
28. Webb, C. P., Van Aelst, L., Wigler, M. H., and Vande Woude, G. F. Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc. Natl. Acad. Sci. USA, 95: 8773-8778, 1998.
29. Lengyel, E., Stepp, E., Gum, R., and Boyd, D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J. Biol. Chem., 270: 23007-23012, 1995.
30. Lengyel, E., Gum, R., Stepp, E., Juarez, J., Wang, H., and Boyd, D. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J. Cell. Biochem., 61: 430-443, 1995.
31. Simon, C., Juarez, J., Nicolson, G. L., and Boyd, D. Effect of PD 098059, a specific inhibitor of mitogen-activated protein kinase kinase, on urokinase expression and in vitro invasion. Cancer Res., 56: 5369-5374, 1996.
32. Duesbery, N. S., Webb, C. P., Leppla, S. H., Gordon, V. M., Klimpel, K. R., Copeland, T. D., Ahn, N. G., Oskarsson, M. K., Fukasawa, K., Paull, K. D., and Vande Woude, G. F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science (Washington DC), 280: 734-737, 1998.
33. Gordon, V. M., Leppla, S. H., and Hewlett, E. L. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect. Immun., 56: 1056-1069, 1988.
34. Milne, J. C., Furlong, D., Hanna, P. C., Wall, J. S., and Collier, R. J. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem., 269: 20607-20612, 1994.
35. Alessi, D. R., Cuenda, A., Cohen, P., Dudley, D. T., and Saltiel, A. R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem., 270: 27489-27494, 1995.
36. Miller, P., DiOrio, C., Moyer, M., Schnur, R. C., Bruskin, A., Cullen, W., and Moyer, J. D. Depletion of the erbB-2 gene produce p185 by benzoquinoid ansamycins. Cancer Res., 54: 2724-2730, 1994.
37. Jeffers, M., Taylor, G. A., Weidner, K. M., Omura, S., and Vande Woude, G. F. Degradation of the met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol. Cell. Biol., 17: 799-808, 1997.
38. Koochekpour, S., Jeffers, M., Wang, P. H., Gong C., Taylor, G. A., Roessler, L. M., Stearman, R., Vasselli, J. R., Stetler-Stevenson, W. G., Kaelin, W. G., Jr., Linehan, W. M., Kausner, R. D., Gnarra, J. R., and Vande Woude, G. F. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell. Biol., 19: 5902-5912, 1999.
39. Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer, 72: 1-22, 1997.
40. Kwaan, H. C. The plasminogen-plasmin system in malignancy. Cancer Metastasis Rev., 11: 291-311, 1992.
41. Shapiro, R. L., Dequette, J. G., Roses, D. F., Nunes, I., Harris, M. N., Kamino, H., Wilson, E. L., and Rifkin, D. B. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res., 56: 3597-3604, 1996.
42. Duffy, M. J., Maguire, T. M., McDermott, E. W., and O'Higgins, N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J. Surg. Oncol., 71: 130-135, 1999.
43. Blasi, F. The urokinase receptor. A cell surface, regulated chemokine. APMIS, 107: 96-101, 1999.
44. Alonso, D. F., Farias, E. F., Ladeda, V., Davel, L., Puricelli, L., and Bal de Kier Joffe, E. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res. Treat., 40: 209-223, 1996.
45. Rabbani, S. A., Harakidas, P., Davidson, D. J., Henkin, J., and Mazar, A. P. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int. J. Cancer, 63: 840-845, 1995.
46. Gescher, A. Analogs of staurosporine: potential anticancer drugs? Gen. Pharmacol., 31: 721-728, 1998.
47. Uehara, Y., Murakami, Y., Mizuno, S., and Kawai, S. Inhibition of transforming activity of tyrosine kinase oncogenes by herbimycin A. Virology, 164: 294-298, 1988.
48. Whitesell, L., Mimnaugh, E. G., De Costa, B., Myers, C. E., and Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA, 91: 8324-8328, 1994.
49. Roe, S. M., Prodromou, C., O'Brien, R., Ladbury, J. E., Piper, P. W., and Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem., 42: 260-266, 1999.
50. Scheibel, T., and Buchner, J. The Hsp90 complex - a super-chaperone machine as a novel drug target. Biochem. Pharmacol., 56: 675-682, 1998.
51. Miller, P., Schnur, R. C., Barbacci, E., Moyer, M. P., and Moyer, J. D. Binding of benzoquinoid ansamycins to p100 correlates with their ability to deplete the erbB2 gene product p185. Biochem. Biophys. Res. Commun., 201: 1313-1319, 1994.
52. Schulte, T. W., Blagosklonny, M. V., Ingui, C., and Neckers, L. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J. Biol. Chem., 270: 24585-24588, 1995.
53. Blagosklonny, M. V., Toretsky, J., and Neckers, L. Geldanamycin selectively destabilizes and conformationally alters mutated p53. Oncogene. 11: 933-939, 1995.
54. Supko, J. G., Hickman, R. L., Grever, M. R., and Malspeis, L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol., 36: 305-315, 1995.